Monte Rosa Therapeutics Inc (GLUE)
Official siteHEALTHCARE • BIOTECHNOLOGY • NASDAQ
Market Cap: $800.67M
Last updated: Nov 17, 2026 at 11:05 AM ET
Monte Rosa Therapeutics Inc (GLUE) Earnings: Report Dates and Results
Monte Rosa Therapeutics (GLUE) is expected to report earnings on Mar 15, 2027. In the quarter ended Sep 30, 2026, Monte Rosa Therapeutics reported EPS of $0.03, above the -$0.10 estimate. It beat the EPS estimate in 4 of the last 8 quarters.
Earnings
Performance (10Y)
Upcoming Estimates
Next Report
GLUE has an expected report date of Mar 15, 2027.
GLUE Earnings Call
The latest GLUE earnings call transcript on file is labeled 2024Q4.
Read the 2024Q4 transcriptEarnings History
Of the 23 quarters below that had an estimate, GLUE beat 12 and missed 11. Revenue for the quarter ended Sep 30, 2026 was $54.37M, up 325.8% from $12.77M a year earlier.
| Quarter ended | EPS | Estimate | Range | Surprise | Result | YoY | Analysts | Revisions | Reported | Revenue |
|---|---|---|---|---|---|---|---|---|---|---|
| Sep 30, 2026 | $0.03 | -$0.10 | -$0.56 - $0.10 | +130.00% | Beat | N/A | 9 | 2 up, 0 down | Nov 5, 2026 | $54.37M |
| Jun 30, 2026 | -$0.43 | -$0.25 | -$0.53 - $0.04 | -72.00% | Miss | N/A | 7 | 2 up, 2 down | Aug 6, 2026 | $8.97M |
| Mar 31, 2026 | -$0.45 | -$0.38 | -$0.51 - -$0.11 | -18.42% | Miss | -178.9% | 6 | 3 up, 1 down | May 7, 2026 | $4.21M |
| Dec 31, 2025 | -$0.55 | -$0.33 | -$0.52 - -$0.02 | -67.58% | Miss | N/A | 7 | 0 up, 1 down | Mar 17, 2026 | $2.78M |
| Sep 30, 2025 | -$0.33 | -$0.35 | -$0.46 - -$0.15 | +5.71% | Beat | N/A | 7 | 0 up, 1 down | Nov 6, 2025 | $12.77M |
| Jun 30, 2025 | -$0.15 | -$0.31 | -$0.51 - -$0.21 | +51.61% | Beat | N/A | 8 | 2 up, 3 down | Aug 7, 2025 | $23.19M |
| Mar 31, 2025 | $0.57 | -$0.32 | -$0.50 - -$0.13 | +278.13% | Beat | N/A | 5 | 3 up, 1 down | May 8, 2025 | $84.93M |
| Dec 31, 2024 | -$0.36 | $0.18 | -$0.66 - $1.40 | -298.94% | Miss | N/A | 9 | 3 up, 0 down | Mar 20, 2025 | $60.65M |
| Sep 30, 2024 | -$0.29 | -$0.47 | -$0.59 - -$0.40 | +38.30% | Beat | N/A | 7 | 0 up, 0 down | Nov 7, 2024 | $9.22M |
| Jun 30, 2024 | -$0.43 | -$0.54 | -$0.60 - -$0.40 | +20.37% | Beat | N/A | 7 | 0 up, 0 down | Aug 8, 2024 | $4.70M |
| Mar 31, 2024 | -$0.53 | -$0.58 | -$0.64 - -$0.51 | +8.62% | Beat | N/A | 7 | 1 up, 0 down | May 9, 2024 | $1.06M |
| Dec 31, 2023 | -$0.58 | -$0.33 | -$0.68 - $0.28 | -75.76% | Miss | N/A | 7 | 0 up, 0 down | Mar 14, 2024 | $8.75M |
| Sep 30, 2023 | -$0.70 | -$0.74 | -$0.78 - -$0.58 | +5.41% | Beat | N/A | 8 | 0 up, 1 down | Nov 9, 2023 | N/A |
| Jun 30, 2023 | -$0.71 | -$0.69 | -$0.76 - -$0.67 | -2.90% | Miss | N/A | 7 | 0 up, 0 down | Aug 10, 2023 | N/A |
| Mar 31, 2023 | -$0.65 | -$0.68 | -$0.74 - -$0.63 | +4.41% | Beat | N/A | 7 | 0 up, 0 down | May 11, 2023 | N/A |
| Dec 31, 2022 | -$0.63 | -$0.62 | -$0.66 - -$0.59 | -1.61% | Miss | N/A | 9 | 0 up, 0 down | Mar 16, 2023 | N/A |
| Sep 30, 2022 | -$0.58 | -$0.59 | -$0.65 - -$0.58 | +1.69% | Beat | N/A | 7 | 0 up, 0 down | Nov 10, 2022 | N/A |
| Jun 30, 2022 | -$0.57 | -$0.47 | N/A | -21.28% | Miss | N/A | 4 | 0 up, 0 down | Aug 11, 2022 | N/A |
| Mar 31, 2022 | -$0.51 | -$0.54 | N/A | +5.56% | Beat | N/A | 5 | 2 up, 0 down | May 11, 2022 | N/A |
| Dec 31, 2021 | -$0.93 | -$0.50 | -$0.57 - -$0.43 | -86.00% | Miss | N/A | 6 | 0 up, 0 down | Mar 29, 2022 | N/A |
| Sep 30, 2021 | -$0.43 | -$0.44 | -$0.48 - -$0.38 | +2.27% | Beat | N/A | 4 | 0 up, 0 down | Nov 10, 2021 | N/A |
| Jun 30, 2021 | -$3.63 | -$0.38 | -$0.47 - -$0.34 | -855.26% | Miss | N/A | 4 | N/A | Aug 12, 2021 | N/A |
| Mar 31, 2021 | -$3.06 | -$0.59 | N/A | -418.64% | Miss | N/A | N/A | N/A | Jun 25, 2021 | N/A |
| Dec 31, 2020 | -$7.18 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2021 | N/A |
| Dec 31, 2019 | -$3.04 | N/A | N/A | N/A | N/A | N/A | N/A | N/A | Mar 31, 2020 | N/A |
Annual EPS
EPS for the fiscal year ended Dec 31, 2025 was -$0.46, after -$1.61 the year before. It was -$3.04 for the year ended Dec 31, 2019, the oldest of the 7 fiscal years shown.
| Fiscal year ended | EPS | Change |
|---|---|---|
| Dec 31, 2025 | -$0.46 | N/A |
| Dec 31, 2024 | -$1.61 | N/A |
| Dec 31, 2023 | -$2.64 | N/A |
| Dec 31, 2022 | -$2.29 | N/A |
| Dec 31, 2021 | -$8.05 | N/A |
| Dec 31, 2020 | -$7.18 | N/A |
| Dec 31, 2019 | -$3.04 | N/A |
Earnings Calls
The only earnings call listed below, 2024Q4 for the period ended Dec 31, 2024, runs about 7,900 words across 12 speakers.
| Call | Period ending | Words | Speakers | Transcript |
|---|---|---|---|---|
| 2024Q4 | Dec 31, 2024 | 7,925 | 12 |
2024Q4 Earnings Call
Opening remarks
Andrew Funderburk Senior Vice President, Investor Relations and Strategic Finance Thank you. Good morning, everyone, and thank you for joining our conference call to discuss the clinical and preclinical updates across our pipeline. With us on today's call are Markus Warmuth, Chief Executive Officer; Filip Janku, Chief Medical Officer; Sharon Townson, Chief Scientific Officer; and Phil Nickson, Chief Business and Legal Officer. Before we begin, I would like to remind everyone that any statements we make or information presented on this call that are not historical facts are forward-looking statements that are based on our current beliefs, plans and expectations and are made pursuant to the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995. Please refer to our annual report and other filings we make with the SEC for our risk factors and other information. With that, I'll turn the call over to Markus.
Markus Warmuth Chief Executive Officer Thank you, Andrew, and thanks everyone for joining us this morning. It's a real pleasure to provide today exciting updates across our clinical and preclinical programs. I'll kick it off by just outlining some of the highlights we will go through in this call today. First, we'll talk about results from our Phase 1 healthy volunteer study of MRT-6160, which very clearly support our path into broad Phase 2 development of this asset. Filip will discuss these results in a minute, but heads up, we really strengthen our conviction in the potential of MRT-6160 as a broadly applied novel treatment approach for immune mediated disease. We will then briefly touch on our NEK7 program, which is on track for an IND submission in the first half of this year. We're also going to provide some details today on the IND enabling studies and some results there, as well as our thoughts on clinical development for this program. And then as sort of a last contribution from the I&I side, I will show you a few slides on how we're using our clean platform to expand our portfolio of oral I&I drugs. Lastly, of course, we'll also get into our oncology programs, but I'll talk about some of those details later in this presentation. So now let's turn to the I&I program, starting with MRT-6160 our VAV1 directed molecular glue degrader. As you can see on Slide 5, VAV1 is a signaling molecule critical in both T and B cell receptor signaling. VAV1 regulates secretion of key immune modulatory cytokines including IL-2, IL-17 interferon-gamma and IL-6. And by doing so, VAV1 is really critical for the interplay of T cells in particular TH17 cells with B cells in immune mediated diseases. And there's a clear evidence that VAV1 is critical for hyperactivation of these pathways.
Frequently Asked Questions About GLUE
When is Monte Rosa Therapeutics's next earnings date?
Monte Rosa Therapeutics's next earnings report is expected for Mar 15, 2027.
Did GLUE beat earnings estimates last quarter?
Yes. Monte Rosa Therapeutics reported EPS of $0.03 for the quarter ended Sep 30, 2026, above the -$0.10 estimate, a 130.00% surprise.
What EPS do analysts expect from GLUE next quarter?
The consensus EPS estimate for Monte Rosa Therapeutics for the quarter ending Dec 31, 2026 is -$0.30 from 11 analysts, with estimates from -$0.57 to -$0.08.
How often does GLUE beat earnings estimates?
Monte Rosa Therapeutics beat the EPS estimate in 4 of the last 8 quarters, with an average surprise of +1.06%.
GLUE pages: Overview, Earnings, Forecast, Financials, Valuation, Competitors